Edition:
United States

BioLine RX Ltd (BLRX.OQ)

BLRX.OQ on NASDAQ Stock Exchange Capital Market

0.81USD
1:24pm EDT
Change (% chg)

$-0.01 (-1.08%)
Prev Close
$0.82
Open
$0.82
Day's High
$0.82
Day's Low
$0.81
Volume
18,500
Avg. Vol
58,185
52-wk High
$1.34
52-wk Low
$0.80

Select another date:

Mon, Mar 26 2018

BRIEF-BioLineRx Announces Notice of Allowance From USPTO for Patent Covering Immunotherapy for Treating Solid Tumors

* BIOLINERX ANNOUNCES NOTICE OF ALLOWANCE FROM USPTO FOR PATENT COVERING AGI-134 - A NOVEL IMMUNOTHERAPY FOR TREATING SOLID TUMORS

BRIEF-Biolinerx Reports Year End 2017 Financial Results

* BIOLINE RX LTD - COMPANY HELD $49.5 MILLION IN CASH, CASH EQUIVALENTS AND SHORT-TERM BANK DEPOSITS AS OF DECEMBER 31, 2017 Source text for Eikon: Further company coverage:

BRIEF-Biolinerx Announces Partial Monotherapy Results From Phase 2A Combat Study In Pancreatic Cancer

* BIOLINERX ANNOUNCES PARTIAL MONOTHERAPY RESULTS FROM PHASE 2A COMBAT STUDY IN PANCREATIC CANCER

BRIEF-Bioline Rx Ltd Files For Mixed Shelf Of Up To $150 Million

* BIOLINE RX LTD FILES FOR MIXED SHELF OF UP TO $150 MILLION - SEC FILING Source text (http://bit.ly/2lcDvcH) Further company coverage:

InVivo to open crop input unit to outside investors

PARIS, Dec 19 French agricultural group InVivo said on Tuesday that it plans to raise 50 million euros ($59 million) for its Bioline division, which develops crop inputs such as seeds and pesticides, by bringing in outside investors.

BRIEF-BioLineRx Reports Overall Survival Results From Long-term Follow-up of Phase 2a Trial in r/r AML

* BIOLINERX REPORTS OVERALL SURVIVAL RESULTS FROM LONG-TERM FOLLOW-UP OF PHASE 2A TRIAL IN R/R AML

BRIEF-BioLine Rx Ltd Q3 ‍loss per ordinary share $0.07​

* BioLine Rx ltd - qtrly ‍loss per ordinary share $0.07​ Source text for Eikon: Further company coverage:

Select another date: